Literature DB >> 23225540

Use of regadenoson in end-stage renal disease.

Ami E Iskandrian, Fadi G Hage, Jaekyeong Heo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23225540     DOI： 10.1007/s12350-012-9658-y

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  16 in total

Review 1.  Selective adenosine agonists and myocardial perfusion imaging.

Authors:  Gilbert J Zoghbi; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2012-02       Impact factor: 5.952

2.  Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Authors:  Toufigh Gordi; Brent Blackburn; Hsiao Lieu
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

3.  Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".

Authors:  Rami Doukky; Raysa Morales Demori; Sidharth Jain; Roy Kiriakos; Victor Mwansa; James E Calvin
Journal:  J Nucl Cardiol       Date:  2012-03-07       Impact factor: 5.952

4.  The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.

Authors:  Rami Doukky; Maria Octavia Rangel; Marwan Wassouf; Rizcallah Dick; Ammar Alqaid; Raysa Morales Demori
Journal:  J Nucl Cardiol       Date:  2012-12-13       Impact factor: 5.952

5.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

6.  Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation.

Authors:  Amar D Patel; Wael S Abo-Auda; Jonathan M Davis; Gilbert J Zoghbi; Mark H Deierhoi; Jaekyeong Heo; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2003-07-15       Impact factor: 2.778

7.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

8.  Role of myocardial perfusion imaging in patients with end-stage renal disease undergoing coronary angiography.

Authors:  Rajesh Venkataraman; Fadi G Hage; Todd Dorfman; Jaekyeong Heo; Raed A Aqel; Angelo M de Mattos; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2008-09-11       Impact factor: 2.778

9.  Safety of regadenoson in patients with end-stage renal disease.

Authors:  Wael Aljaroudi; Daniel Hermann; Fadi Hage; Jaekyeong Heo; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2009-11-18       Impact factor: 2.778

10.  A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

Authors:  Karthik Ananthasubramaniam; Robert Weiss; Bruce McNutt; Barbara Klauke; Kathleen Feaheny; Stan Bukofzer
Journal:  J Nucl Cardiol       Date:  2012-01-19       Impact factor: 5.952
View more
  1 in total

1.  Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.

Authors:  Carlos Salgado Garcia; Carlos Salgado Garcia; Amelia Jimenez Heffernan; Amelia Jimenez Heffernan; Elena Sanchez de Mora; Carlos Ramos Font; Juana Lopez Martin; Francisco Rivera de los Santos; Ignacio Ynfante Milá
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-16       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.